Home › Therapeutic areas › Oncology › Solid Tumors

Solid Tumors (25 companies)

Companies with an active program in Solid Tumors.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ADAG Adagene Oncology 4 Phase 2 $99.4M 10
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $161M 6
APVO Aptevo Therapeutics Oncology 2 Phase 1 $1.6M 8
AVBP ArriVent BioPharma Oncology 3 Phase 3 $553M 7
ARVN Arvinas NeurologyOncology Rare 2 Approved $447M 10
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $4.85B 7
CHRS Coherus Oncology Oncology 1 Approved $74.0M 5
CGEN Compugen Oncology 1 Phase 3 $191M 7
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
ERAS Erasca Oncology 2 Phase 1 $4.87B 5
EXEL Exelixis CardiovascularOncology 3 Approved $16.7B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 $124M 10
IMRX Immuneering Oncology 1 Phase 3 $224M 5
IMNM Immunome Oncology Rare 4 NDA Submitted $2.03B 9
MDNAF Medicenna Therapeutics Oncology 1 Phase 2 $14.8M 10
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $47.7M 8
NBP NovaBridge Biosciences OncologyOphthalmology 1 Phase 2 $95.4M 7
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9
KTTA Pasithea Therapeutics NeurologyOncology Rare 1 Phase 1 $16.0M 4
CATX Perspective Therapeutics Oncology 1 Phase 1 $104M 5
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
RXRX Recursion Pharmaceuticals Oncology 3 Phase 2 $1.69B 6
STRO Sutro Biopharma Oncology 3 Phase 1 $148M 3
VIR Vir Biotechnology Infectious DiseaseOncology Rare 1 Phase 3 $1.58B 6
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28